Pfizer Increases Commitment To Rare Diseases With New Research Unit
Executive Summary
In-licensing and development of so-called "bio-betters" will play critical roles in Pfizer's move, announced June 14, into the rare diseases space. The Rare Diseases Research Unit, to be overseen by Jose Carlos Gutierrez-Ramos, senior VP, Biotherapeutics Research and Development, will be part of Pfizer's worldwide R&D unit devoted to discovering novel medicines for orphan diseases, those affecting fewer than 200,000 patients. Initially it will target hemophilia and muscular dystrophy, both caused by genetic mutations
You may also be interested in...
GSK Continues Emphasis On Rare Diseases With Pact For "Bubble Boy" Gene Therapy
Recently launched GSK rare diseases unit will focus on four primary therapeutic areas.
Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?
Big pharmas from Pfizer to GlaxoSmithKline are expanding their initiatives in niche disease areas, but if Sanofi-Aventis acquires Genzyme as it hopes, the French drug maker could soon emerge as an orphan drug leader
Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?
Big pharmas from Pfizer to GlaxoSmithKline are expanding their initiatives in niche disease areas, but if Sanofi-Aventis acquires Genzyme as it hopes, the French drug maker could soon emerge as an orphan drug leader